1,103 research outputs found
Recommended from our members
More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population
Movassagh et al. (May 25 issue) report an association between a synonymous variant (rs165631) in COMT and a reduced risk of cancer among female carriers of the mutation BRCA1 or BRCA2. The result was based on an analysis involving 25 patients with breast cancer who had germline BRCA1/2 alterations in the Cancer Genome Atlas and 15 presumably cancer-free women with BRCA1/2 nonsense and frameshift alterations in the Exome Sequencing Project of the National Heart, Lung, and Blood Institute (NHLBI). Given the potential for misinterpretation of the results, we feel obliged to correct the impression that rs165631 protects carriers of the BRCA1 or BRCA2 mutation from cancer
Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas
The molecular events that drive the initiation and progression of ovarian adenocarcinoma are not well defined. We have investigated changes in gene expression in ovarian cancer cell lines compared to an immortalized human ovarian surface epithelial cell line (HOSE) using a cDNA array. We identified 17 genes that were under-expressed and 10 genes that were over-expressed in the cell lines compared to the HOSE cells. One of the genes under-expressed in the ovarian cancer cell lines, Id3, a transcriptional inactivator, was selected for further investigation. Id3 mRNA was expressed at reduced levels in 6 out of 9 ovarian cancer cell lines compared to the HOSE cells while at the protein level, all 7 ovarian cancer cell lines examined expressed the Id3 protein at greatly reduced levels. Expression of Id3 mRNA was also examined in primary ovarian tumours and was found in only 12/38 (32%) cases. A search was conducted for mutations of Id3 in primary ovarian cancers using single stranded conformation polymorphism (SSCP) analysis. Only one nucleotide substitution, present also in the corresponding constitutional DNA, was found in 94 ovarian tumours. Furthermore no association was found between LOH at 1p36 and lack of expression of Id3. These data suggest that Id3 is not the target of LOH at 1p36. © 2001 Cancer Research Campaign http://www.bjcancer.co
Common genomic variants associated with breast cancer predict the risk of second primary breast cancer diagnosis
SNPs in lncRNA Regions and Breast Cancer Risk
Long non-coding RNAs (lncRNAs)
play crucial roles in human physiology, and have been found to be
associated with various cancers. Transcribed ultraconserved regions
(T-UCRs) are a subgroup of lncRNAs conserved in several species, and are
often located in cancer-related regions. Breast cancer is the most
common cancer in women worldwide and the leading cause of female cancer
deaths. We investigated the association of genetic variants in lncRNA
and T-UCR regions with breast cancer risk to uncover candidate loci for
further analysis. Our focus was on low-penetrance variants that can be
discovered in a large dataset. We selected 565 regions of lncRNAs and
T-UCRs that are expressed in breast or breast cancer tissue, or show
expression correlation to major breast cancer associated genes. We
studied the association of single nucleotide polymorphisms (SNPs) in
these regions with breast cancer risk in the 122970 case samples and
105974 controls of the Breast Cancer Association Consortium’s
genome-wide data, and also by in silico functional analyses using Integrated Expression Quantitative trait and in silico
prediction of GWAS targets (INQUISIT) and expression quantitative trait
loci (eQTL) analysis. The eQTL analysis was carried out using the
METABRIC dataset and analyses from GTEx and ncRNA eQTL databases. We
found putative breast cancer risk variants (p –5) targeting the lncRNA GABPB1-AS1 in INQUISIT and eQTL analysis. In addition, putative breast cancer risk associated SNPs (p –5) in the region of two T-UCRs, uc.184 and uc.313, located in protein coding genes CPEB4 and TIAL1,
respectively, targeted these genes in INQUISIT and in eQTL analysis.
Other non-coding regions containing SNPs with the defined p-value and
highly significant false discovery rate (FDR) for breast cancer risk
association were discovered that may warrant further studies. These
results suggest candidate lncRNA loci for further research on breast
cancer risk and the molecular mechanisms.</strong
No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer
BACKGROUND: There is evidence that certain mutations in the double-strand break repair pathway ataxia-telangiectasia mutated gene act in a dominant-negative manner to increase the risk of breast cancer. There are also some reports to suggest that the amino acid substitution variants T2119C Ser707Pro and C3161G Pro1054Arg may be associated with breast cancer risk. We investigate the breast cancer risk associated with these two nonconservative amino acid substitution variants using a large Australian population-based case–control study. METHODS: The polymorphisms were genotyped in more than 1300 cases and 600 controls using 5' exonuclease assays. Case–control analyses and genotype distributions were compared by logistic regression. RESULTS: The 2119C variant was rare, occurring at frequencies of 1.4 and 1.3% in cases and controls, respectively (P = 0.8). There was no difference in genotype distribution between cases and controls (P = 0.8), and the TC genotype was not associated with increased risk of breast cancer (adjusted odds ratio = 1.08, 95% confidence interval = 0.59–1.97, P = 0.8). Similarly, the 3161G variant was no more common in cases than in controls (2.9% versus 2.2%, P = 0.2), there was no difference in genotype distribution between cases and controls (P = 0.1), and the CG genotype was not associated with an increased risk of breast cancer (adjusted odds ratio = 1.30, 95% confidence interval = 0.85–1.98, P = 0.2). This lack of evidence for an association persisted within groups defined by the family history of breast cancer or by age. CONCLUSION: The 2119C and 3161G amino acid substitution variants are not associated with moderate or high risks of breast cancer in Australian women
Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients
There is strong evidence that overtly inactivating mutations in RAD51C predispose to hereditary breast and ovarian cancer but the prevalence of such mutations, and whether they are associated with a particular clinical phenotype, remains unclear. Resolving these questions has important implications for the implementation of RAD51C into routine clinical genetic testing. Consequently, we have performed a large RAD51C mutation screen of hereditary breast and ovarian cancer families, and the first study of unselected patients diagnosed with ovarian cancer. Our data confirm a consistent but low frequency (2/335 families) of inactivating RAD51C mutations among families with a history of both breast and ovarian cancer and an absence of mutations among breast cancer only families (0/1,053 families). Our data also provide support for the designation of the missense variant p.Gly264Ser as a moderate penetrance allele
- …